[Urinary enzymes during some antiblastic chemotherapy protocols].
M
M
Airoldi
F
F
Pecchio
F
F
Albanese
V
V
Mastromatteo
A
A
Gariboldi
L
L
Negri
M
M
Fazio
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D015415:Biomarkers; D001943:Breast Neoplasms / Q000188:drug therapy / Q000652:urine; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000652:urine; D007677:Kidney Function Tests; D007684:Kidney Tubules / Q000187:drug effects*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000652:urine; D009113:Muramidase / Q000652:urine*; D009363:Neoplasm Proteins / Q000652:urine; D011237:Predictive Value of Tests; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D012680:Sensitivity and Specificity; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects; D000520:alpha-Glucosidases / Q000652:urine*; D001613:beta 2-Microglobulin / Q000652:urine*
D015415:Biomarkers; D009363:Neoplasm Proteins; D001613:beta 2-Microglobulin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D009113:Muramidase; D000520:alpha-Glucosidases; D011241:Prednisone